Pivotal Novel Countermeasure

Closed Pre-Solicitation Posted

Solicitation number
HT9425-24-RFI-EMZ02
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
San Antonio, Texas 78235, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Health Agency is seeking research and development services related to the "Pivotal validation of a novel countermeasure to improve recovery following traumatic brain injury (TBI) combined with hemorrhagic shock in prolonged field care, delayed evacuation, or remote settings before evacuation." The key objectives are to determine whether intravenous administration of tatM2NX will improve neurological severity score (NSS), memory function, and reduce neuronal cell death and TBI-related biomarkers in a swine model. Responses to the Request for Information (RFI) are due by April 18, 2024 and should be submitted electronically.

This pre-solicitation notice does not have a set-aside designation. The NAICS code for this potential action is 541714 - Research and Development in Biotechnology. The RFI is for information and planning purposes only and does not constitute a solicitation or obligation on the part of the government. No incumbent contractors or potential award values were provided in the information given.

Notice text

See attachment.

Files

File Type Posted
Request-for-Information-Pivotal-Novel-Countermeasure.docx DOCX document

Similar open opportunities

Opportunity Agency Set-aside Responses due
Mild Traumatic Brain Injury (mTBI) Blast Injury Prevention Standards Request for Information Frederick, Maryland 21702, United States Defense Health Agency No set-aside
AN41--Pre-clinical Research: Behavioral Assessment NAICS 541715 Veterans Integrated Service Network 1 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity